Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5671 to 5685 of 7682 results

  1. Further research into implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis should include comparative studies against existing forms of management. Studies should record patient selection, functional outcomes, quality of life and complications. They should also report the nature and timing of any further surgery on the knee and the effect of removing the device. A minimum follow-up period of 2–3 years is needed. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG512/1 Question Further research into implantation of a shock or load absorber for mild to moderate symptomatic medial

    Research recommendation
    Published
    9 June 2015

  2. Further research into joint distraction for ankle osteoarthritis should include comparative studies against the natural history of the disease and against other forms of management. Studies should record patient selection, pain relief, functional outcomes, complications, and quality of life in the long term. They should also report the nature and timing of any further surgery on the ankle.Minimising loss to follow-up is of particular importance. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG538/1 Question Further research into joint distraction for ankle osteoarthritis should include comparative studies

    Research recommendation
    Published
    25 January 2016

  3. Further research into joint distraction for knee osteoarthritis without alignment  correction should include comparative studies against existing forms of management. Studies should record patient selection, joint space measurements in the medium to long term, functional outcomes, quality of life and complications. They should also report the nature and timing of any further surgery on the knee. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG529/1 Question Further research into joint distraction for knee osteoarthritis without alignment correction should

    Research recommendation
    Published
    9 October 2015

  4. Further research into open reduction of slipped capital femoral epiphysis should clearly describe details of clinical presentation (for example, Loder classification), the degree of slip, its stability, and the surgical technique used; including whether surgical dislocation of the hip was done. Outcomes from 2 years onwards should include degree of correction, occurrence of avascular necrosis and need for subsequent hip surgery (and its timing).

    Recommendation ID IPG511/1 Question Further research into open reduction of slipped capital femoral epiphysis should clearly describe details

    Research recommendation
    Published
    9 June 2015

  5. Further research into percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices should take the form of well-conducted trials, which should define patient selection, treatment protocols and location and types of arterial lesions treated, and report long-term patency outcomes. NICE may review this procedure on publication of further evidence.

    Recommendation ID IPG380/1 Question Further research into percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision

    Research recommendation
    Published
    9 June 2015

  6. Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab would be encouraged because it could provide information for future treatment strategies, as would more data on the relative effectiveness of ipilimumab when given as a first-line or second-line treatment.

    Recommendation ID TA319/2 Question Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab

    Research recommendation
    Published
    9 June 2015

  7. Further research into the analytical and clinical validity of the enzyme-linked immunosorbent assay (ELISA) kits (LISA-TRACKER, IDKmonitor and Promonitor) is recommended, specifically on:- the best methods to measure tumour necrosis factor (TNF)-alpha-inhibitor levels in the presence of antibodies to TNF-alpha inhibitors- developing primary reference standards- the accuracy for predicting clinical state- clinically meaningful thresholds.

    Recommendation ID DG22/1 Question Further research into the analytical and clinical validity of the enzyme-linked immunosorbent assay (ELISA)

    Research recommendation
    Published
    21 March 2016

  8. Further research into whether ticagrelor is particularly beneficial in any clinical or biological subgroups would be useful.

    Recommendation ID TA236/2 Question Further research into whether ticagrelor is particularly beneficial in any clinical or biological subgroups

    Research recommendation
    Published
    9 June 2015

  9. Further research into the comparative efficacy and safety of different surgical and ablative treatments would be useful.

    Recommendation ID IPG405/1 Question Further research into the comparative efficacy and safety of different surgical and ablative treatments

    Research recommendation
    Published
    9 June 2015

  10. Further research is needed on the benefits and consequences of detecting preclinical diabetic peripheral neuropathy.

    Recommendation ID MTG38/1 Question Further research is needed on the benefits and consequences of detecting preclinical diabetic peripheral

    Research recommendation
    Published
    3 January 2019

  11. In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed that further research into the treatment benefit of burosumab in young people aged 13 years and over would relieve some of the clinical uncertainty in an age group covered by the marketing authorisation.

    Recommendation ID HST8/1 Question In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed

    Research recommendation
    Published
    22 March 2019

  12. Further research is needed on the impact of faecal calprotectin testing on clinical decision-making when added to current practice. This includes research into optimal cut-off values for tests and the investigation of repeat testing strategies in people with intermediate levels of faecal calprotectin. Development of a consistent definition for the 'intermediate range' is encouraged.

    Recommendation ID DG11/2 Question Further research is needed on the impact of faecal calprotectin testing on clinical decision-making when

    Research recommendation
    Published
    9 June 2015

  13. Further research is needed on the use and clinical utility of faecal calprotectin testing, and support pathways for the long-term management of these conditions in the community should be developed.

    Recommendation ID DG11/1 Question Further research is needed on the use and clinical utility of faecal calprotectin testing, and support

    Research recommendation
    Published
    9 June 2015

  14. Further research is needed to understand the effect of having the additional information provided by the adjunctive colposcopy technologies on anxiety for people having a colposcopy, when this information is shown to a person during the examination.

    Recommendation ID DG32/3 Question Further research is needed to understand the effect of having the additional information provided by

    Research recommendation
    Published
    21 November 2018

  15. What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond to PPIs or H 2   receptor antagonists (H 2 RAs) despite optimum primary care?

    Recommendation ID CG184/5 Question What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in

    Research recommendation
    Published
    15 November 2019